These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 25391991)

  • 21. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia.
    Stein EA; Honarpour N; Wasserman SM; Xu F; Scott R; Raal FJ
    Circulation; 2013 Nov; 128(19):2113-20. PubMed ID: 24014831
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EAS Consensus Panel statement on homozygous FH.
    Stock J
    Atherosclerosis; 2015 Sep; 242(1):323-6. PubMed ID: 26247683
    [No Abstract]   [Full Text] [Related]  

  • 23. A novel type of familial hypercholesterolemia: double heterozygous mutations in LDL receptor and LDL receptor adaptor protein 1 gene.
    Tada H; Kawashiri MA; Ohtani R; Noguchi T; Nakanishi C; Konno T; Hayashi K; Nohara A; Inazu A; Kobayashi J; Mabuchi H; Yamagishi M
    Atherosclerosis; 2011 Dec; 219(2):663-6. PubMed ID: 21872251
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia.
    Alves AC; Etxebarria A; Soutar AK; Martin C; Bourbon M
    Hum Mol Genet; 2014 Apr; 23(7):1817-28. PubMed ID: 24234650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
    Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
    Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of mutations and large rearrangements of the low-density lipoprotein receptor gene in Taiwanese patients with familial hypercholesterolemia.
    Chiou KR; Charng MJ
    Am J Cardiol; 2010 Jun; 105(12):1752-8. PubMed ID: 20538126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetics of familial hypercholesterolemia.
    Brautbar A; Leary E; Rasmussen K; Wilson DP; Steiner RD; Virani S
    Curr Atheroscler Rep; 2015 Apr; 17(4):491. PubMed ID: 25712136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic variation in APOB, PCSK9, and ANGPTL3 in carriers of pathogenic autosomal dominant hypercholesterolemic mutations with unexpected low LDL-Cl Levels.
    Huijgen R; Sjouke B; Vis K; de Randamie JS; Defesche JC; Kastelein JJ; Hovingh GK; Fouchier SW
    Hum Mutat; 2012 Feb; 33(2):448-55. PubMed ID: 22095935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leucine 10 allelic variant in signal peptide of PCSK9 increases the LDL cholesterol-lowering effect of statins in patients with familial hypercholesterolaemia.
    Pisciotta L; Sallo R; Rabacchi C; Wunsch A; Calandra S; Bertolini S
    Nutr Metab Cardiovasc Dis; 2012 Oct; 22(10):831-5. PubMed ID: 21920719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical use of genetic typing in human lipid disorders.
    Brown WV; Breslow J; Ballantyne C
    J Clin Lipidol; 2012; 6(3):199-207. PubMed ID: 22658144
    [No Abstract]   [Full Text] [Related]  

  • 31. No genetic linkage or molecular evidence for involvement of the PCSK9, ARH or CYP7A1 genes in the Familial Hypercholesterolemia phenotype in a sample of Danish families without pathogenic mutations in the LDL receptor and apoB genes.
    Damgaard D; Jensen JM; Larsen ML; Soerensen VR; Jensen HK; Gregersen N; Jensen LG; Faergeman O
    Atherosclerosis; 2004 Dec; 177(2):415-22. PubMed ID: 15530918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. How does mutant proprotein convertase neural apoptosis-regulated convertase 1 induce autosomal dominant hypercholesterolemia?
    Jirholt P; Adiels M; Borén J
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1334-6. PubMed ID: 15297286
    [No Abstract]   [Full Text] [Related]  

  • 33. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population.
    Hooper AJ; Marais AD; Tanyanyiwa DM; Burnett JR
    Atherosclerosis; 2007 Aug; 193(2):445-8. PubMed ID: 16989838
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular basis of familial hypercholesterolemia-like phenotype heterogeneity].
    Wang LY; Lin J; Liu S; Chen BS
    Yi Chuan Xue Bao; 2005 Jul; 32(7):770-7. PubMed ID: 16078748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9 R46L, lower LDL, and cardiovascular disease risk in familial hypercholesterolemia: a cross-sectional cohort study.
    Saavedra YG; Dufour R; Davignon J; Baass A
    Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2700-5. PubMed ID: 25278291
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proprotein convertase subtilisin/kexin type 9 (PCSK9): lessons learned from patients with hypercholesterolemia.
    Awan Z; Baass A; Genest J
    Clin Chem; 2014 Nov; 60(11):1380-9. PubMed ID: 25248569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.
    Futema M; Whittall RA; Kiley A; Steel LK; Cooper JA; Badmus E; Leigh SE; Karpe F; Neil HA; ; Humphries SE
    Atherosclerosis; 2013 Jul; 229(1):161-8. PubMed ID: 23669246
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
    Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.